Knowledge is Healing

You can lose up to 20 pounds in one month, which is considered healthy. The Medifast Diet service delivers the complete well balanced, good looking and tasty meals you need to lose weight directly to your door together with an easy to follow diet plan.

You don’t need shopping or cooking anything more for the diet. Just pick one of the Medifast diet plans - the “5 & 1” weight loss program - and you will never feel hungry again, because you eat 6 times a day.

You won’t gain back the lost weight 

Don’t worry for some people saying that you will gain back the weight after you stop the Medifast diet plan. Of course you will, if you return to your old eating habits. But that happens with all diets if you eventually return to your old meals and eating plan.

Here is what you have to do to avoid the yo-yo effect - stick to the Medifast Diet foods and meals, and follow the plan strictly. This way you will teach yourself new habits and it would be almost impossible to return to your old lifestyle.

Don’t worry if you have tried other diets with no success 

If you have already tried several different unsuccessful diets and weight loss products, the Medifast will still be able to help you lose weight. What you have to do is don’t miss the opportunity that Medifast offers you now, otherwise you risk making more mistakes and at the end you will lose motivation and gain extra weight.

If you wonder how to start and what exactly the Medifast Diet offers you, please visit our Medifast Diet review.

http://lookstare.com/blog/index.php/Health?cat=33

FDA Expands Use of Herceptin for Early Stage Breast Cancer After Primary Therapy
The U. S. Food and Drug Administration (FDA) today expanded the approved use of Herceptin, a biological cancer drug. The new indication is for Herceptin, in combination with other cancer drugs, for the treatment of HER2 positive breast cancer after surgery (lumpectomy or mastectomy). FDA granted priority review to the supplemental application for Herceptin.

Herceptin is a targeted therapy against the HER2 protein on cancer cells. When an excessive amount of HER2 protein is present, it causes cancer cells to grow more rapidly and standard chemotherapy may be less effective. In 1998, FDA approved Herceptin for the treatment of metastatic breast cancer (cancer that has spread to other sites in the body). Today’s approval expands its use to women with cancer only in the breast or lymph nodes which has been removed with surgery. Herceptin should only be prescribed for women diagnosed with HER2 positive breast cancer.

“This is especially good news for women who have breast cancer caused by excessive amounts of the HER-2 protein because this cancer typically has a poor prognosis,” said Dr. Steven Galson, Director for FDA’s Center for Drug Evaluation and Research.

The two studies leading to this new approved indication were conducted by the National Cancer Institute-sponsored Cooperative Groups, a multicenter clinical trials group. Patients in both trials received standard chemotherapy after surgery for breast cancer; approximately half the patients were also given Herceptin. The results from both trials, which included information on nearly 4,000 women, were combined and analyzed in 2005.

Due to positive results, the National Cancer Institute, a part of the National Institutes of Health, ended the studies early. The results showed that women who received Herceptin combined with chemotherapy had fewer relapses (return of breast cancer) for up to three years after surgery. The estimated three-year disease-free rates were 87 percent in women receiving Herceptin and chemotherapy and 75 percent in those receiving chemotherapy alone. It is too soon to know whether Herceptin combined with chemotherapy will increase the cure rate or lower the risk of death from breast cancer.

In the United States there are an estimated 212, 920 new cases of breast cancer and about 40,970 related deaths each year. Approximately 25 percent of women with breast cancer will have tumors that produce excessive amounts of HER2 protein.

The most serious side effect of Herceptin is heart failure (weakening of the heart muscle) that requires medical treatment. Due to the risk of heart disease, only certain patients should receive the drug, including:

Only patients whose tumors are HER2 Positive
Patients who do not have heart failure or weak heart muscle (cardiomyopathy). Patients must be screened for heart function before beginning and during Herceptin treatment.
Less common but serious side effects include infusion reactions (chills, fever, shortness of breath) that rarely are accompanied by lung problems, low white blood counts, and low red blood cell counts.

Herceptin (trastuzumab) is manufactured by Genentech, Inc, San Francisco, CA

http://lookstare.com/blog/index.php/Health?cat=33

FDA Expands Use of Herceptin for Early Stage Breast Cancer After Primary Therapy
The U. S. Food and Drug Administration (FDA) today expanded the approved use of Herceptin, a biological cancer drug. The new indication is for Herceptin, in combination with other cancer drugs, for the treatment of HER2 positive breast cancer after surgery (lumpectomy or mastectomy). FDA granted priority review to the supplemental application for Herceptin.

Herceptin is a targeted therapy against the HER2 protein on cancer cells. When an excessive amount of HER2 protein is present, it causes cancer cells to grow more rapidly and standard chemotherapy may be less effective. In 1998, FDA approved Herceptin for the treatment of metastatic breast cancer (cancer that has spread to other sites in the body). Today’s approval expands its use to women with cancer only in the breast or lymph nodes which has been removed with surgery. Herceptin should only be prescribed for women diagnosed with HER2 positive breast cancer.

“This is especially good news for women who have breast cancer caused by excessive amounts of the HER-2 protein because this cancer typically has a poor prognosis,” said Dr. Steven Galson, Director for FDA’s Center for Drug Evaluation and Research.

The two studies leading to this new approved indication were conducted by the National Cancer Institute-sponsored Cooperative Groups, a multicenter clinical trials group. Patients in both trials received standard chemotherapy after surgery for breast cancer; approximately half the patients were also given Herceptin. The results from both trials, which included information on nearly 4,000 women, were combined and analyzed in 2005.

Due to positive results, the National Cancer Institute, a part of the National Institutes of Health, ended the studies early. The results showed that women who received Herceptin combined with chemotherapy had fewer relapses (return of breast cancer) for up to three years after surgery. The estimated three-year disease-free rates were 87 percent in women receiving Herceptin and chemotherapy and 75 percent in those receiving chemotherapy alone. It is too soon to know whether Herceptin combined with chemotherapy will increase the cure rate or lower the risk of death from breast cancer.

In the United States there are an estimated 212, 920 new cases of breast cancer and about 40,970 related deaths each year. Approximately 25 percent of women with breast cancer will have tumors that produce excessive amounts of HER2 protein.

The most serious side effect of Herceptin is heart failure (weakening of the heart muscle) that requires medical treatment. Due to the risk of heart disease, only certain patients should receive the drug, including:

Only patients whose tumors are HER2 Positive
Patients who do not have heart failure or weak heart muscle (cardiomyopathy). Patients must be screened for heart function before beginning and during Herceptin treatment.
Less common but serious side effects include infusion reactions (chills, fever, shortness of breath) that rarely are accompanied by lung problems, low white blood counts, and low red blood cell counts.

Herceptin (trastuzumab) is manufactured by Genentech, Inc, San Francisco, CA

http://lookstare.com/blog/index.php/Health?cat=33

FDA Expands Use of Herceptin for Early Stage Breast Cancer After Primary Therapy
The U. S. Food and Drug Administration (FDA) today expanded the approved use of Herceptin, a biological cancer drug. The new indication is for Herceptin, in combination with other cancer drugs, for the treatment of HER2 positive breast cancer after surgery (lumpectomy or mastectomy). FDA granted priority review to the supplemental application for Herceptin.

Herceptin is a targeted therapy against the HER2 protein on cancer cells. When an excessive amount of HER2 protein is present, it causes cancer cells to grow more rapidly and standard chemotherapy may be less effective. In 1998, FDA approved Herceptin for the treatment of metastatic breast cancer (cancer that has spread to other sites in the body). Today’s approval expands its use to women with cancer only in the breast or lymph nodes which has been removed with surgery. Herceptin should only be prescribed for women diagnosed with HER2 positive breast cancer.

“This is especially good news for women who have breast cancer caused by excessive amounts of the HER-2 protein because this cancer typically has a poor prognosis,” said Dr. Steven Galson, Director for FDA’s Center for Drug Evaluation and Research.

The two studies leading to this new approved indication were conducted by the National Cancer Institute-sponsored Cooperative Groups, a multicenter clinical trials group. Patients in both trials received standard chemotherapy after surgery for breast cancer; approximately half the patients were also given Herceptin. The results from both trials, which included information on nearly 4,000 women, were combined and analyzed in 2005.

Due to positive results, the National Cancer Institute, a part of the National Institutes of Health, ended the studies early. The results showed that women who received Herceptin combined with chemotherapy had fewer relapses (return of breast cancer) for up to three years after surgery. The estimated three-year disease-free rates were 87 percent in women receiving Herceptin and chemotherapy and 75 percent in those receiving chemotherapy alone. It is too soon to know whether Herceptin combined with chemotherapy will increase the cure rate or lower the risk of death from breast cancer.

In the United States there are an estimated 212, 920 new cases of breast cancer and about 40,970 related deaths each year. Approximately 25 percent of women with breast cancer will have tumors that produce excessive amounts of HER2 protein.

The most serious side effect of Herceptin is heart failure (weakening of the heart muscle) that requires medical treatment. Due to the risk of heart disease, only certain patients should receive the drug, including:

Only patients whose tumors are HER2 Positive
Patients who do not have heart failure or weak heart muscle (cardiomyopathy). Patients must be screened for heart function before beginning and during Herceptin treatment.
Less common but serious side effects include infusion reactions (chills, fever, shortness of breath) that rarely are accompanied by lung problems, low white blood counts, and low red blood cell counts.

Herceptin (trastuzumab) is manufactured by Genentech, Inc, San Francisco, CA

Due to so much demand in detoxification and detox diets, I decided to start talking about detox foot patch system, how it works and does it really help?

Well, first of all you should understand that detox patches are different than weight loss patches. While diet patches deliver weight loss extract to your body, the detox patches simply pull the toxins out and make you feel relaxed, healthy and cleansed.

Why is it called Detox Foot Patch?

They are designed to be placed on your foot. This is the best place to apply the patch, but you can place it on any part of your body where you feel pain and where the toxins actually are (knees, ankles, joints, etc.).

Place the patch on the selected part of your body and go to sleep. On the next morning, you will see changes in the color and the smell of the patch. That’s a good indicator that it has worked all night while you were sleeping.

How the Detox Foot Patch works?
 
The detox patch technology has been developed by Japanese scientists. It took them over 24 years to develop and fully tested the system.

Detox Patch contains Tourmaline which works as a generator of negative ions. Do you feel relaxed after a rain or next to a waterfall? That’s because of the negative ions they produce. It is scientifically proved that negative ions have detoxification effect on your body.

The second active ingredient is wood vinegar essence. Chinese people have used this herb essence for thousands of years to treat infections and irritations. Scientists have discovered that it has the ability to absorb toxins right through your skin.

These two ingredients are a small part of the huge formula on which the technology has been created.

Why should I use it everyday?

People are using the detox patch system to:

 - Relieve pain and discomfort of arthritis.
 - Improve immunity system.
 - Increase vitality and energy.
 - Reduce stress and anxiety.
 - Improve circulation.
 - Improve sleep.
 - Enhance mental focus and concentration.
 - Soothe head aches.

How to start detoxifying your body?

I recommend you to try this easy to use, revolutionary method for releasing the toxins from your body. I found that “Detoxion Patch” offers a free sample with 2 patches. I think this is a great way to detoxify your body and start feeling better day after day.

For more information and requesting the free sample, please visit Detoxion website.